NanoViricides, Inc. President Dr. Anil R. Diwan recently discussed the company’s mission to transform antiviral treatment through its nanoviricide platform during an interview on the Mission Matters Podcast. The company’s lead drug candidate, NV-387, has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles. According to Dr. Diwan, nanoviricides are engineered to prevent viral escape and function independently of patient immune status, offering broad-spectrum potential across diverse patient populations from infants to geriatrics.
NV-387 has completed a Phase I clinical trial with no reported adverse events, and a Phase II clinical trial targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance. The candidate is positioned as a potential empirical therapy for acute respiratory and other viral infections, with an estimated market opportunity exceeding $17 billion by 2030. The company’s technology is based on intellectual property from TheraCour Pharma, Inc., with which NanoViricides has a Memorandum of Understanding for developing drugs based on these technologies for all antiviral infections.
The company’s business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides holds a worldwide exclusive perpetual license to TheraCour’s nanomedicine technology for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue viruses, and certain Coronaviruses. The company intends to obtain licenses for additional viruses like RSV, Poxviruses, and Enteroviruses if initial research proves successful.
Beyond NV-387, NanoViricides is developing other antiviral candidates, including NV-HHV-1 for the treatment of Shingles, and drugs against various viral diseases such as oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company notes that the path to typical drug development is extremely lengthy and requires substantial capital, with no assurance that any pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. More information about the company is available at https://www.nanoviricides.com.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment.